Disease Progression in Frontotemporal Dementia and Alzheimer Disease: The Contribution of Staging Scales

Author(s):Show less -

Lima-Silva, Thais Bento ^{[1, 2]} ; Mioshi, Eneida ^[3] ; Bahia, Valeria Santoro ^[1] ; Cecchini, Mario Amore ^[1] ; Cassimiro, Luciana ^[1] ; Guimaraes, Henrique Cerqueira ^[4] ; Gambogi, Leandro Boson ^[4] ; Caramelli, Paulo ^[4] ; Balthazar, Marcio ^[5] ; Damasceno, Benito ^[5] ; Brucki, Sonia M. D. ^[1] ; de Souza, Leonardo Cruz ^[4] ; Nitrini, Ricardo ^[1] ; Yassuda, Monica Sanches ^{[1, 2]}

Affiliation

^[1] Univ Sao Paulo, Neurol Dept, Sao Paulo - Brazil

^[2] Sch Arts Sci & Humanities, Gerontol, Sao Paulo - Brazil

^[3] Univ East Anglia, Sch Hlth Sci, Norwich, Norfolk - England

^[4] Univ Fed Minas Gerais, Fac Med, Cognit & Behav Neurol Res Grp, Belo Horizonte, MG - Brazil

^[5] Univ Estadual Campinas, Neurol Dept, Campinas - Brazil

• Document type: Journal article
• Source: JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY; v. 34, n. 5, p. 397-404, SEP 2021.
• Web of Science Citations: 1

Abstract

Introduction: There is a shortage of validated instruments to estimate disease progression in frontotemporal dementia (FTD). Objectives: To evaluate the ability of the FTD Rating Scale (FTD-FRS) to detect functional and behavioral changes in patients diagnosed with the behavioral variant of FTD (bvFTD), primary progressive aphasia (PPA), and Alzheimer disease (AD) after 12 months of the initial evaluation, compared to the Clinical Dementia Rating scale-frontotemporal lobar degeneration (CDR-FTLD) and the original Clinical Dementia Rating scale (CDR). Methods: The sample consisted of 70 individuals, aged 40+ years, with at least 2 years of schooling, 31 with the diagnosis of bvFTD, 12 with PPA (8 with semantic variant and 4 with non-fluent variant), and 27 with AD. The FTD-FRS, the CDR, and the 2 additional CDR-FTLD items were completed by a clinician, based on the information provided by the caregiver with frequent contact with the patient. The Addenbrooke Cognitive Examination-Revised was completed by patients. After 12 months, the same protocol was applied. Results: The FTD-FRS, CDR-FTLD, and CDR detected significant decline after 12 months in the 3 clinical groups (exception: FTD-FRS for PPA). The CDR was less sensitive to severe disease stages. Conclusions: The FTD-FRS and the CDR-FTLD are especially useful tools for dementia staging in AD and in the FTD spectrum. (AU)

• FAPESP's process: 11/04804-1 - Functionality and cognitive performance in frontotemporal dementia
• Grantee: Thaís Bento Lima da Silva
• Support Opportunities: Scholarships in Brazil - Master
• FAPESP's process: 16/07967-2 - Neurocognitive markers for the early and differential diagnosis for Alzheimer´s disease and frontotemporal dementia
• Grantee: Monica Sanches Yassuda
• Support Opportunities: Regular Research Grants